AVANIR PHARMACEUTICALS, INC. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 9, 2012

Attached files
FileFilename
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED UNDER RULE 13A-14(A) - AVANIR PHARMACEUTICALS, INC.d345387dex312.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R10.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R5.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R16.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R14.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R13.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R15.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R11.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R12.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R4.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R18.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R1.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R17.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R3.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R7.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R6.htm
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R2.htm
EXCEL - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - AVANIR PHARMACEUTICALS, INC.R9.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER - AVANIR PHARMACEUTICALS, INC.d345387dex321.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED UNDER RULE 13A-14(A) - AVANIR PHARMACEUTICALS, INC.d345387dex311.htm
EX-10.1 - FORM OF INDEMNIFICATION AGREEMENT WITH CERTAIN DIRECTORS AND EXECUTIVE OFFICERS - AVANIR PHARMACEUTICALS, INC.d345387dex101.htm
10-Q - FORM 10-Q - AVANIR PHARMACEUTICALS, INC.d345387d10q.htm
v2.4.0.6
Fair Value Measurements
 6 Months Ended
Mar. 31, 2012
Fair Value Measurements [Abstract]  
FAIR VALUE MEASUREMENTS

3. FAIR VALUE MEASUREMENTS

The Company measures the fair value of certain of its financial assets on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:

 

  •  

Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.

 

  •  

Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

  •  

Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

As of March 31, 2012 and September 30, 2011, the Company’s cash equivalents held in money market mutual funds of approximately $13.3 million and $38.4 million, respectively, are all valued using quoted prices generated by market transactions involving identical assets, or Level 1, as defined by the fair value hierarchy noted above.

 

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by AVANIR PHARMACEUTICALS, INC. and has no official or unofficial affiliation with AVANIR PHARMACEUTICALS, INC.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.